ConductScience.org, home

Paper2013115

Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.

Strocchi E and 9 others. Cancer Chemother Pharmacol, 1991. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses. Papers, record 2013115. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2013115

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Aminoglutethimide in advanced breast cancer: plasma levels and clinical results after low and high doses.
PubMed
Journal
Cancer Chemother Pharmacol
PubMed
Year
1991
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.29
iCite
Revised in PubMed
2019-08-28
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Strocchi EE
2Camaggi CMC M
3Martoni AA
4Cellerino RR
5Miseria SS
6Malacarne PP
7Indelli MM
8Balli MM
9Bonciarelli GG
10Ambroso GG

Source PubMed

Download CSV of authors

Topics17

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
AminoglutethimideMajor topic
Breast NeoplasmsMajor topic
Adult
Aged
Analysis of Variance
Biological Availability
Chromatography, High Pressure Liquid
Cluster Analysis
Discriminant Analysis
Dose-Response Relationship, Drug
Drug Administration Schedule
Drug Evaluation
Female
Humans
Middle Aged
Regression Analysis
Remission Induction

Source PubMed

Download CSV of topics

References16

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
14038654Low-dose aminoglutethimide without steroid replacement in the treatment of postmenopausal women with advanced breast cancer.Eur J Cancer Clin Oncol1985https://conductscience.org/library/papers/4038654PubMed
26221746Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer.Br J Cancer1983https://conductscience.org/library/papers/6221746PubMed
37044525Tamoxifen versus aminoglutethimide versus combined tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma.Cancer Res1982https://conductscience.org/library/papers/7044525PubMed
43978028Observations on the pharmacokinetics of low dose aminoglutethimide in patients with advanced breast cancer.Br J Cancer1985https://conductscience.org/library/papers/3978028PubMed
56177402Treatment of advanced breast cancer with aminoglutethimide: a 14-year experience.Cancer Res1982https://conductscience.org/library/papers/6177402PubMed
66765487Aminoglutethimide: review of pharmacology and clinical use.Pharmacotherapy1981https://conductscience.org/library/papers/6765487PubMed
72943339Aminoglutethimide as an inducer of microsomal enzymes. Part 1: Pharmacological aspects.Breast Cancer Res Treat1986https://conductscience.org/library/papers/2943339PubMed
86487491The effect of acetylator phenotype on the disposition of aminoglutethimide.Br J Clin Pharmacol1984https://conductscience.org/library/papers/6487491PubMed
96147642Low-dose aminoglutethimide in treatment of advanced breast cancer.Lancet1984https://conductscience.org/library/papers/6147642PubMed
103908116Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day.Eur J Cancer Clin Oncol1985https://conductscience.org/library/papers/3908116PubMed
117126424Polymorphically acetylated aminoglutethimide in humans.Br J Cancer1982https://conductscience.org/library/papers/7126424PubMed
126148221Metabolism of aminoglutethimide in humans. Identification of four new urinary metabolites.Drug Metab Dispos1984https://conductscience.org/library/papers/6148221PubMed
133742063Low dose aminoglutethimide (125 mg twice daily) with hydrocortisone for the treatment of advanced postmenopausal breast cancer.Breast Cancer Res Treat1986https://conductscience.org/library/papers/3742063PubMed
14536467Serum aminoglutethimide levels: studies of serum half-life, clearance, and patient compliance.J Clin Pharmacol1979https://conductscience.org/library/papers/536467PubMed
154015950Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients.Br J Cancer1985https://conductscience.org/library/papers/4015950PubMed
163838134Metabolism of aminoglutethimide in humans: quantification and clinical relevance of induced metabolism.Br J Cancer1985https://conductscience.org/library/papers/3838134PubMed

Download CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn Papers
8354015Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio.Clin Pharmacokinet1993https://conductscience.org/library/papers/8354015

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2013115

GET https://conductscience.org/api/papers/v1/2013115/authors